CA-ZYNGA
4.11.2021 14:02:10 CET | Business Wire | Press release
Today, Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced the worldwide launch of FarmVille 3 , the exciting new edition of its iconic FarmVille franchise. The agriculture-simulation social game is now officially available to download on iOS and Android devices worldwide, as well as on the Mac M1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005004/en/
Twelve years – and over 700 million downloads – after the original FarmVille was introduced to the world in 2009, FarmVille 3 is bringing to life a new beautifully crafted world filled with a rich cast of fully animated characters and interactive animals.
Returning to the franchise is the beloved guide Marie, who will welcome back the FarmVille community and greet new players as they build their homesteads and complete challenges. She will be joined by a fresh cast of farmhands with diverse backgrounds and skills who will assist players with new elements in the game, including new customizable farms and animal husbandry.
As players escape into this new world, they can adopt, nurture and raise baby animals from more than 150 breeds – and be rewarded with farm goods, like wool and butter, for their parenting efforts.
“FarmVille 3 immerses players in a visually stunning new FarmVille experience infused with the sense of adventure, social connection and farming spirit that hundreds of millions of fans have come to love,” said Bernard Kim, President of Publishing at Zynga. “We warmly invite a new generation of players to meet the delightful new FarmVille characters and lovable animals who thrive in a gorgeous countryside filled with heart and humor.”
New Game Features
- Variety of animals – Collect, breed and nurture more than 150 breeds of animals, ranging from the mainstay chickens and cows to the exotic tigers and fluffy alpacas
- Diverse farmhands – Meet 30 characters with handy skills – such as baking, fishing, lumberjacking and crafting – that will assist you on your farm-building journey
- A living, breathing world – Control weather patterns with dynamic in-game mechanics to speed up your crop growth, catch more fish or earn more coins
- Customize everything – Dress your farmhands in seasonal outfits such as a pumpkin costume for Halloween or add a personal touch to your farm, animal house or vehicle by picking from a plethora of themed design options such as modern or Victorian decor
- Neighborly social gameplay features – Form your own “co-op” to exchange goods with other players and cooperate to win events and unique decorations
Starting today, players who download the game within the next two weeks will receive a special starter kit with interactive features to help customize their farms, such as decorative elements and the ‘Early Bird’ profile picture.
FarmVille 3 is the latest addition to the FarmVille series, which includes FarmVille 2: Country Escape and FarmVille 2: Tropic Escape .
To view the supporting still and video assets for FarmVille 3 , please click here .
FarmVille 3 is available now for iOS, Android and Mac M1 as a free download.
For more information visit:
www.FarmVille3.com
Facebook
Instagram
Twitter
About Zynga Inc.
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. With massive global reach in more than 175 countries and regions, Zynga has a diverse portfolio of popular game franchises that have been downloaded more than four billion times on mobile including CSR Racing ™, Empires & Puzzles ™, Golf Rival ™, Hair Challenge ™, Harry Potter: Puzzles & Spells ™, High Heels! ™, Merge Dragons! ™, Merge Magic! ™, Queen Bee ™, Toon Blast ™, Toy Blast ™, Words With Friends ™ and Zynga Poker ™. With Chartboost, a leading mobile advertising and monetization platform, Zynga is an industry-leading next-generation platform with the ability to optimize programmatic advertising and yields at scale. Founded in 2007, Zynga is headquartered in California with locations in North America, Europe and Asia. For more information, visit www.zynga.com or follow Zynga on Twitter , Instagram , Facebook or the Zynga blog .
About FarmVille
Launched on Facebook in 2009, FarmVille spawned a social gaming franchise that has drawn over 700 million installs worldwide across Facebook, web and mobile platforms. Offering players the ability to grow virtual crops and build digital farms together in real-time, FarmVille has entertained its fans in FarmVille 2 , FarmVille 2: Country Escape and FarmVille 2: Tropic Escape . FarmVille 3, a game developed by Zynga Helsinki, aims to reinvent the classic farm building genre and showcase the modern mechanics of mobile gaming.
FORWARD-LOOKING STATEMENTS
This message contains forward-looking statements relating to future game events and features. Forward-looking statements often include words such as “will,” “expect,” “plan,” “intend,” and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties and assumptions is or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s web site at www.sec.gov .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
